

MARCUS A. NEUBAUER, M.D.
CURRICULUM VITAE

PROFESSIONAL DESIGNATION

Licensed to Practice Medicine:

Kansas
Missouri

Board Certifications:

American Board of Internal Medicine—Medical Oncology	1993
American Board of Internal Medicine	1991
National Board of Medical Examiners; Parts I, II, III	

EDUCATIONAL BACKGROUND

University of Washington	<i>Seattle, WA</i>
Oncology/Hematology Fellowship	1993
University of Kansas	<i>Kansas City, KS</i>
Internal Medicine Residency	1991
Internal Medicine Internship	1989
Doctorate of Medicine	1988
University of Washington	<i>Seattle, WA</i>
Bachelor of Arts—Microbiology	1984

PROFESSIONAL EXPERIENCE

Kansas City Cancer Centers (Formerly Oncology & Hematology Associates), Overland Park, KS	1997-Present
North Puget Oncology; Mt. Vernon, WA	1996-1997
Valley Internal Medicine; Renton, WA	1995-1996

Oncology & Hematology Associates; Kansas City, MO 1993-1995

PROFESSIONAL APPOINTMENTS

Kansas Society of Clinical Oncology (KSCO)
President 2004-Present

Kansas/Western Missouri Medicare
Member, Carrier Advisory Committee—Oncology 2001-Present

U.S. Oncology
Co-Chair, Lung Cancer Research Committee 2001-Present
Executive Committee, Pharmacy & Therapeutics Committee 2000-Present
Member, Pharmacy & Therapeutics Committee 1997-Present

Kansas City Cancer Center
Chair, Pharmacy & Therapeutics Committee 2000-Present
Chair, Quality Improvement Committee 1997-Present

Overland Park Regional Medical Center
Hematology/Oncology Chair 2000-2004
Internal Medicine Chair 2004-2005

St. Luke's-Shawnee Mission Hospice
Medical Director 1997-2001

Kansas/Western Missouri 2001-Present
Carrier Advisory Committee Member, Oncology

ASCO, Clinical Practice Committee 2004-Present
Member

HOSPITAL AFFILIATIONS

Menorah Medical Center Overland Park, KS 1997-present

Overland Park Regional Medical Center	Kansas City, MO	1997-present
Providence Medical Center	Kansas City, KS	1997-present
Shawnee Mission Medical Center	Shawnee Mission, KS	1997-present
St. Luke's South	Overland Park, KS	1997-present

PRESENTATIONS (NOT ALL-INCLUSIVE)

Update on Lung Cancer, Post-ASCO Meeting, June, 2004

“Update on Breast Cancer.” OB-GYN Conference, Overland Park Regional Medical Center, 1998.

“Transfusion Guideline for the Intensive Care Unit.” Critical Care Symposium, Kansas City Southwest Clinical Society, 1995.

“The Management of Pain in Cancer Patients.” Outreach Program, St. Joseph Health Center, 1994.

“Disseminated Histoplasmosis in Patients with AIDS.” House Staff Day, University of Kansas, 1991.

“Hypercoagulable States.” Resident Conference, University of Kansas, 1991.

“Autologous Bone Marrow Transplantation.” Resident Conference, University of Kansas, 1989.

PUBLICATIONS AND ABSTRACTS

“Results of a Phase II Trial Utilizing Gemcitabine in Patients with Non-Small Cell Lung Cancer and a Performance Status of 2.” **M. Neubauer**, C. Reynolds, M. Joppert, T. Whittaker, H. Ghaddar, T. Marsland. Clinical Lung Cancer, January 2005, Vol. 6: Page 245-249.

“Results of a Phase II Trial Utilizing Gemcitabine in Patients with Non-Small Cell Lung Cancer and a Performance Status of 2.” **M. Neubauer**. Proceedings of ASCO, 2004, Abstract #7121.

“Results of a Phase II Study of Carboplatin Plus Gemcitabine in Patients with Untreated Extensive Small Cell Lung Cancer.” **M. Neubauer**, R. Heaven, J.

Olivares, A. Otsuka, E. Paxchold, C. Sirridge, D. Ilegbod, T. Tuttle, L. Asmar. Lung Cancer, July 15, 2004. Vol. 46: Page 369-375.

“Results of a Phase II Multicenter Trial of Weekly Docetaxel (Taxotere) Plus Gemcitabine (Gemzar) as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer.” **Neubauer, M.**, Garfield, D., Khan, M., Dakhil, S., Kuefler, P., Raju, R., Asmar, L. Lung Cancer, May 25, 2004.

“Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patient with Extensive Small Cell Lung Cancer with ECOG Performance Status of 2 or age Greater than 70.” **M. Neubauer.** Journal of Clinical Oncology, May 15, 2004, Volume 22, No. 10. Page 1872-1877.

“A Phase II Study of Carboplatin and Gemcitabine in Patients with Untreated Extensive Small Cell Lung Cancer.” C. Sirridge, **M. Neubauer**, E. Paschold, A. Otsuka, R. Heaven, D. Ilegbod, L. Asmar. Proceedings ASCO 2003: Abstract #2825.

“Phase II Study of Weekly Paclitaxel and Carboplatin in Patients with Extensive Small Cell Lung Cancer with ECOG Performance Status of 2 or Age ≥ 70 .” **M.A. Neubauer**, J. Rubins, J. Schwartz, D. Ilegbod, L. Asmar. Proceedings ASCO 2003: Abstract #2707.

“Phase II Study of First Line Chemotherapy Using CT 2103 in Patients with Non-Small Cell Lung Cancer who are ≥ 70 Years of Age or Performance Status (PS) = 2.” **M.A. Neubauer**, J. Rubins, J. Schwartz, D. Ilegbod, L. Asmar. Proceedings ASCO 2003: Abstract #2626.

“Quality Improvement and Ethics: Performance Improvement in an Oncology Practice.” Hennessy, J., **Neubauer, M.A.** The Journal of Clinical Ethics, Vol. 13, Number 4, Winter 2002.

“Phase II Trial of Paclitaxel, Ifosfamide, and Carboplatin in Extensive-Stage Small Cell Lung Cancer.” Socinski, M.A., **Neubauer, M.A.**, Olivares, J., Ketchel, S., Tynan, M., Moore, M., Lee, J., Davis, K., Schell, M., Garfield, D. Lung Cancer: 1-7, 2002.

“Phase II Trial of 5-Flourouracil plus Eniluracil in Patients with Advance Pancreatic Cancer: A Southwest Oncology Group Study.” Rothenberg, M.L., Benedetti, J.K., MacDonald, J.S., Seay, T.E., **Neubauer, M.A.**, George, C.S., Taknak, M.S.,

Giguere, J.K., Pruitt, B.T., Abbruzzese, J.L. Annals of Oncology 13: 1576-1582, 2002.

“Phase II Study of MGI-114 Administered Intravenously for Five Days Every 28 Days to Patients with Metastatic Colorectal Cancer.” Hoff, P., **Neubauer, M.A.**, et. al. Annals of Oncology. 2002. (Accepted for publication.)

“Phase II Study of Sequential Chemotherapy Followed by Oral Maintenance Therapy with ORXEL® (UFT + Leucovorin) in Patients with Stage IIIB and IV Non-Small Cell Lung Cancer.” Asmar, L., Bristol-Myers Squibb, Plainsboro, NJ, Garfield, D.H., Kahn, M.M., Marsland, T.A., **Neubauer, M.A.**, U.S. Oncology, Houston, TX, Vukelja, S.J. Proceedings, American Society of Clinical Oncology, 2002. Abstract #2745.

“Multicenter Phase II Trial of Paclitaxel, Ifosfamide, and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer.” Garfield, D., Ketchel, S., Lee, Ji-Hyun, Moore, M., **Neubauer, M.A.**, Olivares, J., Socinski, M.A., Tynan, M. Proceedings, American Society of Clinical Oncology. 2002. Abstract # 1330.

“Phase II Trial of Weekly Docetaxel (Taxotere) Plus Gemcitabine (Gemzar) as First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer.” Asmar, L., Dakhil, S., Garfield, D., Khan, M., Kuefler, P., **Neubauer, M.A.**, Raju, R. Proceedings, American Society of Clinical Oncology. 2001. Abstract #2760.

“A Phase II Study of Weekly Paclitaxel (Taxol) Followed by Carboplatin and Etoposide in the Treatment of Extensive Small Cell Lung Cancer.” Asmar, L., Ferri, D., Garfield, D., Gregurich, M., **Neubauer, M.A.** Proceedings, American Society of Clinical Oncology. 2001.

“Lymphokine-activated Killer Cell Activity is Present in Fresh and Crypreserved Peripheral Blood Stem Cells and in the Peripheral Blood after Peripheral Blood Stem Cell Transplant.” Bensinger, W.I., Benyunes, M.C., Buckner, C.D., Fefer, A., Lindgren, C.L., **Neubauer, M.A.**, Thompson, J.A. Bone Marrow Transplantation. 13:331-316, 1994.

“Phase IB Trial of Pentoxifylline and Ciproflaxacin in Patients Treated with Interleukin-2 and Lymphokine Activated Killer Cell Therapy for Metastatic Renal Cell Carcinoma.” Benyunes, M.C., Bianco, J.A., Fefer, A., **Neubauer, M.A.**, Slattery, J.T., Thompson, J.A. Cancer Research, 54:3436-3441, 1994.

“Pentoxifylline and Ciprofloxacin Reduce the Toxicity of High-dose Infusion IL-2 and LAK Cell Therapy.” Benyunes, M.C., Bianco, J.A., Fefer, A., **Neubauer, M.A.**, Thompson, J.A. Proceedings, American Society of Clinical Oncology, May, 1993.

“Disseminated Histoplasmosis in Patients with AIDS.” Bodensteiner, D., **Neubauer, M.A.** Southern Medical Journal. 85:1166-1170, 1992.

RESEARCH

“A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With Metastatic Colorectal Cancer.” US Oncology Protocol No. 05009. (Principal Investigator). 2005.

“A Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Investigate The Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-497115-GR, A Thrombopoietin Receptor Agonist, Administered at 30, 50 and 75mg As Oral Tablets Once-Daily For 6 Weeks To Adult Male and Female Subjects With Refractory, Chronic Immune Thrombocytopenic Purpura (TRA100773).” US Oncology Protocol No. 05011. (Principal Investigator). 2005.

“A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide plus Dexamethasone (Thal-Dex) versus DOXIL plus Thalidomide plus Dexamethasone (DOXIL-Thal-Dex) in Subjects with Newly Diagnosed Multiple Myeloma.” US Oncology Protocol No. 04127. (Principal Investigator). 2005.

“A Phase II Open Label Study of E7389 (Halichondrin B Analog) In Patients with Advanced/Metastatic Breast Cancer Previously Treated with Chemotherapy Including an Anthracycline and A Taxane (E7389-A001-201).” US Oncology Protocol No. 04131. (Principal Investigator). 2005.

“Randomized, two arm, placebo controlled study to compare the efficacy of intravenous loading doses followed by maintenance treatment with intravenous ibandronic acid versus zoledronic acid in patients with skeletal metastases experiencing moderate to severe pain(BO18040).” US Oncology Protocol No. 04048. (Principal Investigator). 2004.

“A Phase II Study of Alimta as First-Line Chemotherapy for Advanced or Metastatic Breast Cancer.” US Oncology Protocol No. 02100. (Principal Investigator). 2004.

“A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer (EGF30008).” US Oncology Protocol No. 03076. (Principal Investigator). 2004.

“A Phase III, Randomized, Open-Label, Multicenter Study Comparing GW572016 and Capecitabine (Xeloda) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer (EGF100151).” US Oncology Protocol No. 04028. (Principal Investigator). 2004.

“A randomized, three arm multinational phase III study to investigate bevacizumab (q3w or q2w) in combination with either intermittent capecitabine plus oxaliplatin (“XELOX”) (q3w) or fluorouracil/ leucovorin with oxaliplatin (“FOLFOX-4”) versus “FOLFOX-4” regimen alone as adjuvant chemotherapy in colon carcinoma (BO17920).” US Oncology Protocol No. 04062. (Principal Investigator). 2004.

“A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFR Levels by Immunohistochemistry Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy (20030250).” US Oncology Protocol No. 04072. (Principal Investigator). 2004.

“Phase II Study of Capecitabine + Irinotecan (Xeliri) + Erbitux (cetuximab) as First Line Therapy in Patients with Advanced and /or Metastatic Colorectal Cancer.” US Oncology Protocol No. 03117. (Principal Investigator). 2004.

“A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy (20030167).” US Oncology Protocol No. 03086. (Principal Investigator). 2004.

“A Multi-Center, Open-Label, Non-Randomized Phase II Study Of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (ELSA-2004-001).” US Oncology Protocol No. 04100. (Principal Investigator). 2004.

“Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer.” US Oncology Protocol No. 04017. (Principal Investigator). 2004.

“Phase II Study Of E7389, Halichondrin B Analog, In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy (E7389-A001-202).” US Oncology Protocol No. 04108. (Principal Investigator). 2004.

“A Randomized Trial of Carboplatin/Gemcitabine vs. Gemcitabine alone in PS2 Patients with Advanced (Stage IIIB or IV) NSCLC.” US Oncology Protocol No. 03012. (Principal Investigator). 2004.

“Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy (IMCL CP02-0452).” US Oncology Protocol No. 04107. (Principal Investigator). 2004.

“A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel (ILX651-241).” US Oncology Protocol No. 04024. (Principal Investigator). 2004.

“Circulating Tumor Cells and the Prediction of Overall Survival in Patients with Androgen Independent Prostate Cancer Entering onto Chemotherapy.” US Oncology Protocol No. 04098. (Principal Investigator). 2004.

“Phase II Trial of Gemzar Plus Paraplatin (Plus Herceptin in HER2+ Patients) in Metastatic Breast Cancer Patients.” US Oncology Protocol No. 02099. (Principal Investigator). 2004.

“Phase II Trial of Taxotere + Eloxatin in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma.” US Oncology Protocol No. 03065. (Principal Investigator). 2004.

“A Phase II Study of Gemzar Plus Zometa in Stage IV Cancer of the Pancreas (CZOL446EUS81).” US Oncology Protocol No. 03080. (Principal Investigator). 2004.

“A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients with MTAP-Deficient Cancer.” US Oncology Protocol No. 02-109. (Principal Investigator). 2003.

“A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC).” US Oncology Protocol No. 02-033. (Principal Investigator). 2003.

“Clinical Protocol CA225006: A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma.” Bristol Myers Squibb, Co./US Oncology Protocol No. 02-064. (Principal Investigator). 2003

“A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients with Inoperable Locally Advanced or Metastatic Melanoma.” ILEX Oncology/ US Oncology Protocol No. 03-067. (Principal Investigator). 2003.

“A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine plus LY293111 Compared to Gemcitabine plus Placebo in Patients with Locally Advanced or Metastatic Pancreatic Cancer.” US Oncology Protocol No. 02122. (Principal Investigator). 2003.

“A randomized phase II trial of Alimta/Cisplatin and Alimta/Carboplatin in extensive stage small cell lung cancer.” US Oncology Protocol No. 02112. (Principal Investigator). 2003.

“Phase II Clinical Trial of Bi-Weekly Dosing of Irofulven in Patients with Unresectable Hepatocellular Carcinoma.” US Oncology Protocol No. 02077. (Principal Investigator). 2003.

“An Open Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline, a Taxane, and Capecitabine (or Fluoropyrimidine) (E7070-A001-211).” US Oncology Protocol No. 03069. (Principal Investigator). 2003.

“Phase II Trial of Combination Therapy with Xeloda and Weekly Paclitaxel for Metastatic Breast Cancer.” US Oncology Protocol No. 00001. (Principal

Investigator). 2003.

“An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) ("XELOX") versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients with Metastatic Colorectal Cancer who have Received Prior Treatment with CPT-11 in Combination with 5-FU/LV as First Line Therapy(Roche study# NO16967A).” US Oncology Protocol No. 02119. (Principal Investigator). 2003.

An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) ("XELOX") versus Fluorouracil/Leucovorin as Adjuvant Therapy for Patients who have Undergone Surgery for Colon Carcinoma, AJCC/UICC Stage III (Dukes Stage C) (16968).” US Oncology Protocol No. 02117. (Principal Investigator). 2003.

“Phase II, Randomized, Open-Label Study of 2 Schedules of Single-Agent Oral Irinotecan in Patients with Metastatic Breast Cancer who have Experienced Failure of Prior Therapy with an Anthracycline, a Taxane and Capecitabine (CPT-APO-0047-1).” US Oncology Protocol No. 03009. (Principal Investigator). 2003.

“A Multi-Center, Multi-National, Double-Blind, Randomized Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients with Hormone Refractory Prostate Cancer Previously Treated with One Cytotoxic Chemotherapy Regimen (GPC SAT3-03-01).” US Oncology Protocol No. 03085. (Principal Investigator). 2003.

A Randomized, Phase III Multicenter Trial of Gemcitabine in Combination with Carboplatin or Paclitaxel versus Paclitaxel plus Carboplatin in Patients with Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer.” US Oncology Protocol No. 03023. (Principal Investigator). 2003.

“A prospective, randomized, open label, phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in previously untreated or treated b-cell chronic lymphocytic leukemia.” US Oncology Protocol No. 03017. (Principal Investigator). 2003.

“A Randomized, Open-Label, Multicenter, Phase III Trial Comparing Regimens of Adriamycin plus Cytosan Followed by Either Taxotere or Taxotere plus Xeloda

as Adjuvant Therapy for Female Patients with High-Risk Breast Cancer.” US Oncology Protocol No. 01062. (Principal Investigator). 2002.

“Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by elective Paclitaxel Consolidation versus Paclitaxel and Carboplatin Followed by elective Paclitaxel Consolidation in Patients with Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian tube Carcinoma (D) (B9E-US-S302).” US Oncology Protocol No. 02044. (Principal Investigator). 2002.

“Open, Multicenter, Controlled Study of Exemestane (Aromasin) with or without Celecoxib (Celebrex) in Postmenopausal Women with Advanced Breast Cancer (ABC) Having Progressed on Tamoxifen (NQ8-01-02-013).” US Oncology Protocol No. 01091. (Principal Investigator). 2002.

“Phase I/II Study of Campath in Patients with Relapsing or Refractory Non-Hodgkin's Lymphoma.” US Oncology Protocol No. 02091. (Principal Investigator). 2002.

“A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC): Tariquidar in Lung Cancer (TLC1) (TQD LUNG 001).” US Oncology Protocol No. 02018. (Principal Investigator). 2002.

“A Randomized, Multi-center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5-FU, (Day 1 & 8), and Oral Capecitabine (Day 1-14); with Celecoxib versus Placebo as First-line Treatment for Patients With Metastatic Colorectal Cancer, Protocol Amended April 23, 2004 to include Bevacizumab (CPTAIV-0020-411).” US Oncology Protocol No. 02063. (Principal Investigator). 2002.

“A Randomized Phase III Trial of Gemzar versus Doxil with Crossover Treatment Option for Patients with Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy (B9E-US-S301).” US Oncology Protocol No. 02089. (Principal Investigator). 2002.

“A Phase II Trial of Xeloda and Taxotere in Hormone-Refractory Prostate Cancer (HRPC).” US Oncology Protocol No. 01090. (Principal Investigator). 2002.

“A pilot Phase II study to determine the safety and efficacy of the combination of ONTAK® (Denileukin Diftitox) with CHOP in peripheral T-cell lymphoma (PIND #35).” US Oncology Protocol No. 01058. (Principal Investigator). 2002.

“A Phase II Study of Glutamine Supplementation in Patients Receiving Weekly Taxol for Metastatic Breast or Non-Small Cell Lung Cancers: A Joint Taxol Neuropathy Team and US Oncology, Inc. Study.” US Oncology Protocol No. 00-030. (Principal Investigator). 2001.

“A Phase II Study of Carboplatin and Gemcitabine in Patients with Untreated Extensive Small Cell Lung Cancer.” US Oncology Protocol No. 00-059. (Principal Investigator). 2001.

“A Phase Ib/II Study of Thoracic Radiation with Concurrent Gemcitabine for Patients with Limited Small Cell Lung Cancer.” US Oncology Protocol No. 00-068. (Principal Investigator). 2001.

“Randomized Phase III study of Exemestane for 5 Years Versus Tamoxifen for 2.5-3 Years Followed by Exemestane for a Total of 5 Years as Adjuvant Therapy for Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients.” US Oncology Protocol No. 00010. (Principal Investigator). 2001.

“BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients with Metastatic Breast Cancer.” US Oncology Protocol No. 01037. (Principal Investigator). 2001.

“A Phase II Clinical Trial of ABI-007 (a Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly in Taxane Resistant Patients With Metastatic Breast Cancer.” US Oncology Protocol No. 01030. (Principal Investigator). 2001.

“A Phase III, Randomized, Double-Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) versus Chemotherapy Alone in Patients with Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy.” US Oncology Protocol No. 01045. (Principal Investigator). 2001.

“A Phase II Study of Weekly Paclitaxel and Carboplatin in Patients with Extensive Small Cell Lung Cancer with ECOG Performance Status of 2 or Age \geq 70.” US Oncology Protocol No. 99-107. (Principal Investigator). 2000.

“A Randomized, Multicenter Trial Comparing Regimens of Doxorubicin + Cyclophosphamide Followed by Paclitaxel (every 3 weeks for four cycles) and Doxorubicin + Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Female Patients with High Risk Breast Cancer.” US Oncology Protocol No. 99-106. (Principal Investigator). 2000.

“Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients with Unresectable, Locally Recurrent or Metastatic Breast Cancer (B9E-MC-JHQ.” US Oncology Protocol No. 99039. (Principal Investigator). 1999.

PROFESSIONAL MEMBERSHIPS

American Society of Clinical Oncology
Kansas City Clinical Oncology Program
Southwest Oncology Group